Ranbaxy Of India To Close Three Southeast Asia Plants
This article was originally published in PharmAsia News
India's Ranbaxy Laboratories plans to close three of its Southeast Asia plants, one each in China, Malaysia and Vietnam. The strategy is intended to save the firm about $30 million, according to sources, but Ranbaxy would not comment. The company is said to be seeking buyers for the plants as the firm's first move to sell assets in the wake of its acquisition by Japan's Daiichi Sankyo. The Ranbaxy Guangzhou China plant was the first Sino-Indian partnership across business sectors and the first plant in China to get good manufacturing practices approval. (Click here for more
You may also be interested in...
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.
Two leading, independent bodies of French scientists, doctors and pharmacists are calling for OTC drugs containing pseudoephedrine to be reverse-switched to prescription-only status over safety fears.